Beyond iPSC Based Disease Models A Translatable Drug Discovery Platform for Status Epilepticus 

Epilepsy is a common neurological disorder characterized by recurrent spontaneous seizures.  Up to 40% of patients do not respond or develop resistance to available anti-epileptic drug treatments. The establishment of more translatable human cell-based assays can address the unmet need for new therapy strategies by complementing pre-clinical drug development to increase success rates in human patients. 

​

During this webinar, Dr Daniel Haag, Head of Neuroscience at NeuCyte, will share how the NeuCyte team has built an iPSC-derived neural in vitro platform with complex electrophysiology-based phenotypic readouts to evaluate the efficacy of novel compounds and approved AEDs (antiepileptic drugs) for the treatment of Status Epilepticus.